

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 October 2024 (17.10.2024)



(10) International Publication Number
WO 2024/216154 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) C07D 451/02 (2006.01)
C07D 403/12 (2006.01) C07D 451/14 (2006.01)
C07D 403/14 (2006.01) C07D 453/02 (2006.01)
C07D 405/14 (2006.01) A61K 31/497 (2006.01)
C07D 413/14 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/024431

(22) International Filing Date:

12 April 2024 (12.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/496,146 14 April 2023 (14.04.2023) US
63/591,862 20 October 2023 (20.10.2023) US
63/564,604 13 March 2024 (13.03.2024) US

(71) Applicant: **BLUEPRINT MEDICINES CORPO-
RATION** [US/US]; 45 Sidney Street, Cambridge, Massa-
chusetts 02139 (US).

(72) Inventors: **BIFULCO, JR., Neil**; 15 Lillian Ave., Sud-
bury, Massachusetts 01776 (US). **BROOIJMANS, Natas-
ja**; 43 Concord Square, Apt. 2, Boston, Massachusetts
02118 (US). **FANG, Cheng**; 45 Sidney Street, Cambridge,
Massachusetts 02139 (US). **KIM, Joseph L.**; 45 Sid-
ney Street, Cambridge, Massachusetts 02139 (US). **PER-
OLA, Emanuele**; 45 Sidney Street, Cambridge, Mass-
achusetts 02139 (US). **RAMSDEN, Philip D.**; 45 Sid-
ney Street, Cambridge, Massachusetts 02139 (US). **VAR-
GAS, Richard**; 45 Sidney Street, Cambridge, Massachu-
setts 02139 (US). **WENGLOWSKY, Steven Mark**; 266
Harvard Street, Apt. 6, Cambridge, Massachusetts 02139
(US).

(74) Agent: **IMLAY, Hunter et al.**; GOODWIN PROCTER
LLP, 100 Northern Avenue, Boston, Massachusetts 02210
(US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: CDK2 INHIBITORS



(57) Abstract: The present disclosure provides, in part, a compound represented by struc-
tural Formula (I) or a pharmaceutically acceptable salt thereof useful for treating a cancer.

WO 2024/216154 A1